Immunogenicity of meningococcal PBP2 during natural infection and protective activity of anti-PBP2 antibodies against meningococcal bacteraemia in mice

Journal of Antimicrobial Chemotherapy

Volumn 57, Issue 5, 2006, Pages 924-930

  Zarantonelli, Maria Leticia ^a   Antignac, Aude ^a,b   Lancellotti, Marcelo ^a   Guiyoule, Annie ^a   Alonso, Jean Michel ^a   Taha, Muhamed Kheir ^a  

^a INSTITUT PASTEUR   (France)

^b ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Animal model; Neisseria meningitidis; Penicillin binding proteins; Vaccine

Indexed keywords

IMMUNOGLOBULIN G; MENINGOCOCCUS VACCINE; PENICILLIN BINDING PROTEIN; PENICILLIN BINDING PROTEIN 2 IMMUNOGLOBULIN G ANTIBODY; POLYCLONAL ANTIBODY; RECOMBINANT PENICILLIN BINDING PROTEIN 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOGENICITY; INFECTION PREVENTION; MENINGOCOCCOSIS; MOUSE; NEISSERIA MENINGITIDIS; NONHUMAN; PASSIVE IMMUNIZATION; PROTEIN ANALYSIS; PROTEIN PURIFICATION; STRAIN DIFFERENCE;

ANIMALS; ANTIBODIES, MONOCLONAL; BLOOD BACTERICIDAL ACTIVITY; CLONING, MOLECULAR; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN G; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; MICE; MICE, INBRED BALB C; NEISSERIA MENINGITIDIS; PENICILLIN-BINDING PROTEINS; RABBITS; RECOMBINANT FUSION PROTEINS;

EID: 33645834310     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl066     Document Type: Article

References (29)

1. Quagliarello VJ, Scheld WM. Treatment of bacterial meningitis. N Engl J Med 1997; 336: 708-16.
2. Antignac A, Ducos-Galand M, Guiyoule A et al. Neisseria meningitidis strains isolated from invasive infections in France (1999-2002): phenotypes and antibiotic susceptibility patterns. Clin Infect Dis 2003; 37: 912-20.
3. Saez Nieto JA, Vazquez JA, Marcos C. Meningococci moderately resistant to penicillin. Lancet 1990; 336: 54.
4. Claassen I, Meylis J, van der Ley P et al. Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine. Vaccine 1996; 14: 1001-8.
5. Rokbi B, Mignon M, Maitre-Wilmotte G et al. Evaluation of recombinant transferrin-binding protein B variants from Neisseria meningitidis for their ability to induce cross-reactive and bactericidal antibodies against a genetically diverse collection of serogroup B strains. Infect Immun 1997; 65: 55-63.
6. Fredriksen JH, Rosenqvist E, Wedege E et al. Production, characterization and control of MenB-vaccine 'Folkehelsa': An outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann 1991; 14: 67-79.
7. Holst J, Feiring B, Fuglesang JE et al. Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. Vaccine 2003; 21: 734-7.
8. Sierra GV, Campa HC, Varcacel NM et al. Vaccine against group B Neisseria meningitidis: Protection trial and mass vaccination results in Cuba. NIPH Ann 1991; 14: 195-207.
9. Maiden MC. Population genetics of a transformable bacterium: The influence of horizontal genetic exchange on the biology of Neisseria meningitidis. FEMS Microbiol Lett 1993; 112: 243-50.
10. Spratt BG, Cromie KD. Penicillin-binding proteins of gram-negative bacteria. Rev Infect Dis 1988; 10: 699-711.
11. Barbour AG. Properties of penicillin-binding proteins in Neisseria gonorrhoeae. Antimicrob Agents Chemother 1981; 19: 316-22.
12. Parkhill J, Achtman M, James KD et al. Complete DNA sequence of a serogroup A strain of Neisseria meningitidis Z2491. Nature 2000; 404: 502-6.
13. Tettelin H, Saunders NJ, Heidelberg J et al. Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science 2000; 287: 1809-15.
14. Antignac A, Kriz P, Tzanakaki G et al. Polymorphism of Neisseria meningitidis penA gene associated with reduced susceptibility to penicillin. J Antimicrob Chemother 2001; 47: 285-96.
15. Spratt BG. Resistance to antibiotics mediated by target alterations. Science 1994; 264: 388-93.
16. Antignac A, Boneca IG, Rousselle JC et al. Correlation between alterations of the penicillin-binding protein 2 and modifications of the peptidoglycan structure in Neisseria meningitidis with reduced susceptibility to penicillin G. J Biol Chem 2003; 278: 31529-35.
17. Taha MK, Giorgini D, Ducos-Galand M et al. Continuing diversification of Neisseria meningitidis W135 as a primary cause of meningococcal disease after emergence of the serogroup in 2000. J Clin Microbiol 2004; 42: 4158-63.
18. Kellogg DS Jr, Peacock WL Jr, Deacon WE et al. Neisseria gonorrhoeae. I. Virulence genetically linked to clonal variation. J Bacteriol 1963; 85: 1274-9.
19. Vazquez JA, Arreaza L, Block C et al. Interlaboratory comparison of agar dilution and Etest methods for determining the MICs of antibiotics used in management of Neisseria meningitidis infections. Antimicrob Agents Chemother 2003; 47: 3430-4.
20. Parge HE, Bernstein SL, Deal CD et al. Biochemical purification and crystallographic characterization of the fiber-forming protein pilin from Neisseria gonorrhoeae. J Biol Chem 1990; 265: 2278-85.
21. Abdillahi H, Poolman JT. Typing of group-B Neisseria meningitidis with monoclonal antibodies in the whole-cell ELISA. J Med Microbiol 1988; 26: 177-80.
22. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1989.
23. Welsch JA, Moe GR, Rossi R et al. Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity. J Infect Dis 2003; 188: 1730-40.
24. Deghmane AE, Taha MK. The Neisseria meningitidis adhesion regulatory protein CrgA acts through oligomerization and interaction with RNA polymerase. Mol Microbiol 2003; 47: 135-43.
25. Taha MK, Deghmane AE, Antignac A et al. The duality of virulence and transmissibility in Neisseria meningitidis. Trends Microbiol 2002; 10: 376-82.
26. Ohwada A, Sekiya M, Hanaki H et al. DNA vaccination by mecA sequence evokes an antibacterial immune response against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 1999; 44: 767-74.
27. Senna JP, Roth DM, Oliveira JS et al. Protective immune response against methicillin resistant Staphylococcus aureus in a murine model using a DNA vaccine approach. Vaccine 2003; 21: 2661-6.
28. Dessen A, Mouz N, Gordon E et al. Crystal structure of PBP2x from a highly penicillin-resistant Streptococcus pneumoniae clinical isolate: A mosaic framework containing 83 mutations. J Biol Chem 2001; 276: 45106-12.
29. Sabhnani L, Manocha M, Tomar D et al. Yersinia pestis F1 antigen: A correlation between antibody titres and subclass distribution with differential avidity in different inbred mouse strains. Int Immunopharmacol 2003; 3: 1413-8.